AstraZeneca (AZN) · Pharmaceuticals
AstraZeneca Q2 2026 earnings: summary, key numbers & outlook
Results filed 27 Jul 2026 · Quarter ended 30 Jun 2026
Press release ↗Investor relations ↗
Summaries and transcripts are machine-generated and can contain errors.
In brief
AstraZeneca won its first US approval for Baxfendy, a first-in-class hypertension medicine, while the CARDIO-TTRansform trial of Wainua in ATTR-CM missed its primary endpoint.
AstraZeneca's first half brought 30 approvals in major regions since its Q4 2025 results, including US approval of Baxfendy for hypertension. Oncology led growth, with Enhertu, Imfinzi, Calquence and Truqap all expanding and new Enhertu and Datroway breast cancer indications approved. Respiratory and rare disease also grew, led by Tezspire and Strensiq. Farxiga lost US exclusivity, China volume-based procurement weighed on Emerging Markets, and Wainua's ATTR-CM trial missed its endpoint.
Management says it is on track for its $80 billion 2030 revenue ambition, which it says assumes both successes and setbacks. It is leaning on more than twenty high-value readouts over the next 18 months and on new licensing deals: Zegfrovy for EGFR-mutated lung cancer from Dizal and a respiratory PDE3/4 inhibitor from CTTQ. The tension is that generic and procurement pressure on older medicines must be offset by new launches and pipeline results that are not guaranteed.
No call transcript for this quarter, so this summary also draws on: Joshua Thompson ↗, Nordic Life Science ↗, Kalkine Media ↗.
Key numbers
- Total Revenue growth, H1 2026 (CER)
- 6%
- Core EPS growth, H1 2026 (CER) · non-GAAP
- 11%
| Segment or metric | Value | Change |
|---|---|---|
| Approvals in major regions since Q4 2025 results | 30 |
Where each number comes from
- Total Revenue growth, H1 2026 (CER): “Total Revenue up 6%, with double-digit growth in Oncology and Rare Disease offsetting headwinds from Farxiga US loss of exclusivity and China volume-based procurement”
- Core EPS growth, H1 2026 (CER): “Core Operating profit and Core EPS increased 11%”
- Approvals in major regions since Q4 2025 results: “30 approvals in major regions since Q4 2025 results”
Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.
Outlook
| Metric | Period | Outlook |
|---|---|---|
| Core tax rate | FY 2026 | 18-22% |
Key takeaways
Baxfendy wins US approval as first-in-class hypertension drug
The FDA approved Baxfendy on the BaxHTN data, and a Japan submission followed. It opens a new cardiovascular franchise as Farxiga and Brilinta face generics, though sales were only $3m so far.
Oncology breadth expands through Enhertu and Datroway approvals
Enhertu gained US approvals in early and neoadjuvant HER2+ breast cancer and an EU approval for HER2-positive solid tumours, while Datroway won US approval in first-line triple-negative breast cancer. Enhertu grew 32% at CER in H1.
Wainua's ATTR-CM trial miss tests the cardiovascular pipeline
CARDIO-TTRansform did not meet its primary endpoint, which management called disappointing. Wainua still grew 44% in H1, but the miss closes a hoped-for expansion into ATTR-CM.
Older cardiometabolic products face generics and procurement pressure
Farxiga lost US exclusivity, and Brilinta and roxadustat declined on generics. China volume-based procurement also pressured Emerging Markets, showing how much new launches must replace.
Dizal and CTTQ deals add lung cancer and respiratory assets
AstraZeneca licensed worldwide rights to Zegfrovy for EGFR exon 20 NSCLC, with $600m upfront, and TQC3721, a PDE3/4 inhibitor for respiratory indications, with $200m upfront. Both extend existing therapeutic franchises through external assets.
Questions
What was AstraZeneca's most important product news this quarter?
The US approval of Baxfendy, a first-in-class medicine for hypertension, with a Japan submission following. Management also pointed to eight first approvals in major markets in the first half.
What went wrong in the pipeline?
The Phase III CARDIO-TTRansform trial of Wainua in ATTR-CM did not meet its primary endpoint, and Imfinzi's EMERALD-2 trial in adjuvant HCC and Ultomiris's TMA-313 trial in HSCT-TMA also missed. Management said it was disappointed but confident in the broader pipeline.
Which medicines are driving growth?
Oncology is the main driver, led by Imfinzi, Enhertu, Calquence and Truqap. Tezspire, Strensiq and Wainua also grew strongly.
Which products or markets are under pressure?
Farxiga lost US exclusivity, and Brilinta and roxadustat declined on generics. China is also a headwind from volume-based procurement and a more competitive Tagrisso market.
What deals did AstraZeneca announce?
In July 2026 it licensed Zegfrovy from Dizal for lung cancer, with $600m upfront, and TQC3721 from CTTQ for respiratory disease, with $200m upfront. Both are subject to closing conditions.
Documents
SEC filing